论文部分内容阅读
目的探讨63例人肺癌中Bcl-2蛋白的表达与VEGF和血管新生的关系。方法采用免疫组织化学方法,以抗CD34单抗标记血管内皮细胞以测定血管新生,抗Bcl-2单抗标记Bcl-2蛋白,抗VEGF165单克隆抗体检测VEGF的表达。结果所有肺癌组织均有不同程度血管新生,iMVD4～138.7(44.5±29)/×400,Bcl-2蛋白表达率44.4%(28/63),VEGF的表达率50.8%(32/63)。Bcl-2表达在Ⅰ、Ⅱ期(55.3%)明显高于Ⅲ、Ⅳ期(28%)(P<0.05),而与组织类型无关;VEGF与组织类型、临床分期、患者性别、年龄等临床参数无关;所有肺癌组织中Bcl-2蛋白表达与VEGF和血管新生未见明显相关。结论Bcl-2蛋白表达与VEGF和血管新生未见相关;人肺癌的发生发展Bcl-2蛋白过度表达有关;Bcl-2蛋白表达可能为肺癌早期事件,可作为评定预后的生物学指标。
Objective To investigate the relationship between Bcl-2 protein expression and VEGF and angiogenesis in 63 cases of human lung cancer. Methods Immunohistochemistry was used to detect vascular endothelial cells by anti-CD34 monoclonal antibody to detect angiogenesis, anti-Bcl-2 monoclonal antibody Bcl-2 protein and anti-VEGF165 monoclonal antibody to detect the expression of VEGF. Results All lung cancer tissues had different degrees of angiogenesis. The expression rates of iMVD4 ~ 138.7 (44.5 ± 29) / × 400, 44.4% (28/63), and 50.8% (32/63) The expression of Bcl-2 was significantly higher in stageⅠandⅡ (55.3%) than in stage Ⅲ and Ⅳ (28%) (P <0.05), but not with the type of tissue. The expression of Bcl-2 was correlated with histological type, clinical stage, gender and age No correlation was found between the expression of Bcl-2 protein and VEGF and angiogenesis in all lung cancer tissues. Conclusions Bcl-2 protein expression is not related to VEGF and angiogenesis; Bcl-2 protein overexpression is associated with the occurrence and development of human lung cancer; Bcl-2 protein expression may be an early event of lung cancer, which can be used as a biological indicator to evaluate the prognosis.